Small Molecule Developability Assessment

Small molecule developability assessment aims to determine whether a compound possesses the necessary physicochemical and biopharmaceutical properties to support successful formulation and targeted delivery to the site of action. As a preclinical CRO specializing in oncology, Alfa Cytology provides comprehensive developability assessment services for small molecule candidates, covering physicochemical characterization, in vitro ADME profiling, in vivo pharmacokinetics, and early safety evaluation—empowering you to make informed, science-driven decisions at every stage from Hit-to-Lead through Lead Optimization.

Introduction to Small Molecule Developability Assessment

Developability refers to the potential of a small molecule compound to possess ADME properties and safety profiles sufficient to enter Phase I clinical trials. The discovery and development of small molecule drugs face formidable challenges—long timelines, high investment, and substantial risk. Statistics show that over 60% of candidate drug failures are attributed to suboptimal ADME/T properties rather than a lack of pharmacological activity. Poor solubility, low permeability, rapid metabolism, and CYP inhibition-mediated drug-drug interaction risks—these seemingly minor issues can cause even the most potent lead compounds to fail before reaching the clinic. Conducting systematic developability assessment of small molecule candidates prior to CMC development and formal preclinical safety evaluation enables early identification of high-risk molecules, pinpoints critical liabilities, guides targeted structural optimization, and provides a scientific foundation for candidate selection. This approach not only reduces the probability of late-stage attrition but also ensures that R&D resources are strategically allocated to molecules with the greatest translational potential—ultimately increasing the likelihood of successful clinical advancement.

Fig. 1 Large-scale in silico ADMET modeling for small-molecule developability prediction. (Sergazy S, et al.; 2025)

Our Services

For small molecule drugs, developability assessment centers on key attributes including target binding pocket analysis, physicochemical properties, metabolic stability, pharmacokinetic profiles, and early safety parameters. Our services span the entire drug discovery continuum—from Hit-to-Lead through Lead Optimization. By integrating multi-dimensional data encompassing solubility, permeability, metabolic stability, PK characteristics, and preliminary toxicity screening, we help you prioritize candidates with the highest probability of successful clinical translation before committing to costly CMC development and preclinical studies—systematically de-risking your R&D program.

Tumor Model Library

The value of developability assessment lies in identifying candidate molecules with the greatest potential for clinical translation—but the assessment itself is not the endpoint. Whether a candidate molecule can demonstrate antitumor activity in disease-relevant models is what ultimately determines whether the program moves forward. Alfa Cytology's Tumor Model Library enables your candidates to transition seamlessly from early developability assessment to efficacy validation.

Our model library encompasses:

Areas of Expertise in Oncology

Leveraging our oncology expertise, the small molecule developability assessment platform supports a broad spectrum of solid tumors and hematological malignancies, backed by extensive experience in the development and validation of novel therapeutics across diverse indications.

Optimize your small molecule leads with Alfa Cytology's data-driven developability assessment, integrating ADMET prediction, physicochemical profiling, and PK/PD evaluation to reduce late-stage attrition. Please don't hesitate to contact us to advance your drug discovery.

For research use only.